Prosecution Insights
Last updated: November 20, 2026
Application No. 18/198,085

FLEXIBLE ANALYTE SENSORS

Final Rejection §103§112
Filed
May 16, 2023
Priority
Jan 19, 2017 — provisional 62/448,295 +1 more
Examiner
WEARE, MEREDITH H
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
DexCom Inc.
OA Round
6 (Final)
51%
Grant Probability
Moderate
7-8
OA Rounds
4m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
367 granted / 726 resolved
-19.4% vs TC avg
Strong +32% interview lift
Without
With
+31.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
47 currently pending
Career history
784
Total Applications
across all art units

Statute-Specific Performance

§101
14.3%
-25.7% vs TC avg
§103
38.1%
-1.9% vs TC avg
§102
8.0%
-32.0% vs TC avg
§112
32.0%
-8.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 726 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after 16 March 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendment to the claims filed 22 May 2026 has been entered. Claim(s) 1 is/are currently amended. Claim(s) 7 and 16-18 has/have been canceled. Claim(s) 1-6, 8-15 and 19-25 is/are pending. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation (BRI) using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The BRI of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) (or pre-AIA 35 U.S.C. 112, sixth paragraph) is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f): (A) the claim limitation uses the term "means" or "step" or a term used as a substitute for "means" that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term "means" or "step" or the generic placeholder is modified by functional language, typically, but not always linked by the transition word "for" (e.g., "means for") or another linking word or phrase, such as "configured to" or "so that"; and (C) the term "means" or "step" or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word "means" (or "step") in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f). The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word "means" (or "step") in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f). The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word "means" (or "step") are being interpreted under 35 U.S.C. 112(f), except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word "means" (or "step") are not being interpreted under 35 U.S.C. 112(f), except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word "means," but are nonetheless being interpreted under 35 U.S.C. 112(f) because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: a "sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor in claim 1. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f), it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If Applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f), Applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of pre-AIA 35 U.S.C. 112, second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim(s) 1-6, 8-15 and 19-25 is/are rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Regarding claim 1 and claims dependent thereon, the limitation "a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor" is indefinite. As noted above, said limitation has been interpreted to invoke 35 U.S.C. 112(f). Applicant discloses, "In embodiments in which the sensor is a non-freestanding sensor ex vivo, sensor deployment mechanisms may include specialized components for deployment of a non-freestanding sensor. For example, with a freestanding sensor, the sensor may be disposed within a lumen of an inserter needle that is inserted into the skin of the host along with the sensor and withdrawn, leaving the sensor embedded in the skin. For a non-freestanding sensor, in some embodiments, a folding-unfolding mechanism or a coiling-uncoiling mechanism may be provided within the needle to control the position of the sensor and, if desired, to leverage internal void space inside the lumen of the cylindrical needle. In embodiments, in which the sensor is too soft for needle/cannula delivery, a preconnected c-needle deployment system may be used." There is no/insufficient disclosure of the "specialized components for deployment of a non-freestanding sensor" (¶ [0324]). At best, Applicant refers to additional generic "mechanisms" for "folding-unfolding," "coiling-uncoiling," etc., but does not disclose the structure of said mechanisms. Accordingly, there is no (or insufficient) disclosed corresponding structure that performs the entire claimed function(s) of the above-noted limitation, such that the limitation is indefinite. See MPEP 2181(III). Additionally, the scope of "freestanding" in view of Applicant's amendments to the claims is unclear. It is unclear if "freestanding" encompasses any sensor "that holds is shape and position without any supporting forces and regardless of the orientation thereof with respsect to gravity (¶ [0161]); encompasses any sensor that "holds its shape during dipping operations" (¶ [0210]); encompasses any sensor that is "relatively stiff" (¶ [0249]); is limited to "a sensor having a Young's modulus and/or a flexural modulus of greater than 500 MPa or having a buckling force that is substantially greater than the weight of the sensor under gravity" (¶ [0259]); encompasses any sensor that may "bend or deform when a sufficient force 800 is applied thereto and may return…to the same shape and position as prior to application of force 800, when the force is withdrawn" (¶ [0260]); etc. The scope of "non-freestanding" is similarly unclear. It is unclear if "non-freestanding" encompasses any sensor that is "tissue compliant" (¶ [0123]); any sensor that is "relatively flexible" (¶ [0249]); is limited to "a sensor having a Young's modulus and/or a flexural modulus of less than 500 MPa or having a buckling force that is less than 0.01 N or…substantially less than the weight of the sensor under gravity" (¶ [0259]); encompasses any sensor that may "bend or deform at various locations when a sufficient force…is applied thereto and may remain…in the bent or deformed shape, when the force is withdrawn" (¶ [0260]); etc. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of pre-AIA 35 U.S.C. 112, first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim(s) 1-6, 8-15 and 19-25 is/are rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 1 and claims dependent thereon, as discussed above, the limitation "a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor" invokes 35 U.S.C. 112(f) and is indefinite based on failure of the specification to disclose corresponding structure that performs the entire claimed function(s). Accordingly, the above-noted limitation also lacks adequate written description. See MPEP 2181(IV). Additionally, Applicant discloses, "In embodiments in which the sensor is a non-freestanding sensor ex vivo, sensor deployment mechanisms may include specialized components for deployment of a non-freestanding" (¶ [0324]). Claim 1 indicates the analyte sensor is a freestanding sensor ex vivo, while paragraph [0324] indicates that "sensor deployment mechanisms" are utilized for sensors that are non-freestanding ex vivo, such that the above-noted limitation additionally encompasses and/or is directed to new matter. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: Determining the scope and contents of the prior art. Ascertaining the differences between the prior art and the claims at issue. Resolving the level of ordinary skill in the pertinent art. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-6 and 9-11 is/are rejected under 35 U.S.C. 103 as being unpatentable over US 2011/0230735 A1 (Wolfe); or alternatively, over Wolfe in view of US 2015/0202351 A1 (Kaplan). Regarding claim 1, Wolfe discloses/suggests an analyte sensor system comprising: an analyte sensor configured for in vivo use (e.g., Fig. 10), the analyte sensor comprising: an elongated core (central core 402) comprising a layer of conductive material covering at least a portion of the elongated core (wires 401; ¶¶ [0094]-[0097]; etc.); a working electrode disposed on the elongated core (¶¶ [0094]-[0097] electrode areas, or electrodes, are formed on the wires by removing a portion of the electrically insulating layer that has been extruded over the wire, wherein typically one of these electrodes is a working electrode); and a membrane covering at least a portion of the working electrode, wherein the membrane comprises an enzyme layer (¶ [0094] coating on the electrode area(s) or the entire wire, said coating having a plurality of constituents, e.g., ¶¶ [0098]-[0116], including an analyte sensing constituent, such as an enzyme, e.g., ¶¶ [0100]-[0107]; etc.), wherein the analyte sensor is configured to transform from a freestanding sensor (i.e., relatively rigid) sensor to a non-freestanding sensor (i.e., relatively flexible) responsive to being inserted/implanted (e.g., ¶ [0089] the sensor can be more stiff during the implant and then soften during wear); an inserter needle having a lumen in which the analyte sensor is disposed, and a sharpened distal tip configured to pierce skin of a host (¶¶ [0089] needle carrying/enclosing the sensor; Fig. 5, needle 514; ¶ [0208] needle used to insert sensor; etc.), wherein the analyte sensor is configured to be at least partially inserted into the skin of the host from the lumen of the inserter needle, and wherein the inserter needle is withdrawn from the skin of the host after the in vivo insertion of the analyte sensor (¶ [0129]; ¶ [0208]; etc.); and a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor (insertion tool 560; ¶ [0129]; ¶ [0208]; etc.). As discussed with respect to rejections under 35 U.S.C. 112(b) above, the scope of "freestanding" and "non-freestanding" are indefinite. Wolfe discloses the analyte sensor is relatively stiff ex vivo and relatively flexible in vivo, thereby meeting at least one reasonable interpretation of the above-noted terms consistent with the specification (e.g., ¶ [0249]). Alternatively/Additionally, Wolfe discloses chemistry, such as the enzyme layer, may be deposited on the electrode areas of the analyte sensor after the wire is positioned around the core (e.g., ¶ [0089]), and methods of depositing said chemistry include, e.g., dip and dry processes (e.g., ¶ [0066]). Further alternatively/additionally, Kaplan similarly discloses a component configured for in vivo insertion, wherein the component is configured to transform from freestanding to non-freestanding responsive to being inserted in tissue (e.g., ¶¶ [0017]-[0018]), wherein, while free-standing, the component has a Young's modulus at least comparable to or greater than that of a target tissue (¶ [0064]), which may be subcutaneous tissue (¶ [0014]), and, while non-freestanding, the component has a Young's modulus reduced by 2- to 1000-fold relative to the freestanding state (e.g., ¶ [0131]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the system of Wolfe with the analyte sensor being configured to transform from a freestanding sensor (e.g., having material properties sufficient to hold its shape while penetrating a solution surface for dipping, while penetrating tissue, etc.) to a non-freestanding sensor responsive to being inserted in tissue as disclosed/suggested by Kaplan in order to ensure the analyte sensor does not buckle or deform during chemistry/enzyme application (Wolfe, ¶ [0089], ¶ [0066]; etc.), during sensor insertion through tissue (Kaplan, ¶ [0065]), thereby precisely reaching a target region of tissue (Kaplan, ¶ [0065]), etc., while enabling the sensor to be mechanically compliant with the target tissue when inserted/implanted (Kaplan, ¶ [0067]). Wolfe/Wolfe as modified only appears to expressly disclose the analyte sensor may transform in response to in vivo temperature (e.g., ¶ [0089]; ¶ [0092] shape memory materials include "heat softening" materials; etc.). As such, Wolfe does not expressly disclose the analyte sensor transforms in response to in vivo hydration. However, Wolfe does disclose the core material may include a polymer (e.g., ¶ [0089]), and generally suggests the core material having shape memory properties permits the core/sensor to be stiffer ex vivo and to soften in vivo (¶ [0089]). In view of the above, at the time the invention was effectively filed, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the system of Wolfe with the analyte sensor transforming in response to in vivo hydration because Applicant has not disclosed that an analyte sensor that transforms in response to in vivo hydration provides an advantage, is used for a particular purpose, or solves a stated problem. Rather, Applicant discloses sensors that transform in response to hydration and sensors that transform in response to, e.g., temperature, as suitable alternatives (e.g., ¶ [0321]). As no evidence has been provided to the contrary, one of ordinary skill in the art would have expected Applicant's invention to perform equally well with the temperature-responsive core material disclosed by Wolfe because either arrangement permits the analyte sensor to be relatively stiff ex vivo and relatively flexible in vivo. Alternatively/Additionally, Kaplan discloses/suggests a component configured for in vivo insertion, wherein the component is configured to transform from freestanding to non-freestanding responsive to in vivo hydration of the component (e.g., ¶ [0018]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the system of Wolfe with the analyte sensor being configured to transform responsive to in vivo hydration (e.g., the core comprising a silk-based material) as disclosed/suggested by Kaplan as a simple substitution of one suitable transformable material (or condition for initiating such a transformation) for another to yield no more than predictable results. See MPEP 2143(I)(B). Regarding claims 2 and 9, Wolfe as modified discloses/suggests the elongated core comprises a titanium alloy (e.g., ¶ [0089] nickel titanium alloy) which has a Young's modulus between 500 MPa and 147 GPa before the in vivo insertion (see, e.g., Wikipedia, mailed herewith). Alternatively/Additionally, Kaplan discloses an elongated core comprising copper and a dynamic silk coating (e.g., Figs. 4-5), wherein the elongated core has a Young's modulus between 500 MPa and 147 GPa before the in vivo insertion (see, e.g., Wikipedia, mailed herewith, wherein copper has a Young's modulus between 110-128 GPa; Kaplan, ¶ [0064]; etc.). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the analyte sensor of Wolfe with the elongated core comprising copper, wherein the elongated core has a Young's modulus between 500 MPa and 147 GPa before the in vivo insertion, as disclosed and/or suggested by Kaplan as a simple substitution of one suitable elongated core material(s) for another to yield no more than predictable results. See MPEP 2143(I)(B). Regarding claim 3, Wolfe as modified discloses/suggests but does not expressly disclose the elongated core has a Young's modulus less than 5 GPa before the in vivo insertion. However, at the time the invention was effectively filed, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Wolfe with the elongated core having a Young's modulus less than 5 GPa before the in vivo insertion because Applicant has not disclosed that the claimed range provides an advantage, is used for a particular purpose, or solves a stated problem. As no evidence has been provided to the contrary, one of ordinary skill in the art would have expected Applicant's invention to perform equally well with the elongated core having any Young's modulus before the in vivo insertion that enables the sensor to be sufficiently "freestanding" (e.g., holding its shape during manufacturing processes, holding its shape during insertion through tissue, etc.) because either arrangement permits to be relatively stiff ex vivo and relatively flexible in vivo. Alternatively/Additionally, Kaplan discloses, before in vivo insertion, the component may have a Young's modulus at least comparable or up to 90% greater than that of a target tissue (e.g., ¶ [0064]). Since Applicant acknowledges the elastic modulus of subcutaneous tissue is known or reported to be 0.12-23 kPa (e.g., ¶ [0122]), it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Wolfe with the elongated core having a Young's modulus less than 5 GPa before the in vivo insertion (e.g., 0.12 kPa – 47.7 kPa) as disclosed/suggested by Kaplan in order to provide the sensor with sufficient stiffness for penetrating subcutaneous tissue during insertion therein (Kaplan, ¶ [0122]). Regarding claims 4-6, Wolfe as modified does not expressly disclose the elongated core has a buckling force of less than 0.02 N, less than 0.01 N, or less than 0.0001 N after the in vivo insertion. However, Kaplan discloses buckling force is a function of at least Young's modulus (e.g., Kaplan, ¶ [0065] a Young's modulus sufficient to yield a buckling force), such that Wolfe as modified discloses there is an inherent buckling force associated with each of the freestanding and non-freestanding sensor states, wherein said buckling force is a function of the Young's modulus of the analyte sensor/elongated core in each respective state, and said buckling force is greater before in vivo insertion (Kaplan, ¶ [0337]). Accordingly, at the time the invention was effectively filed, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the analyte sensor of Wolfe with analyte sensor (e.g., a stimulus-responsive elongated core thereof) having a buckling force of less than 0.25 N, less than less 0.02 N, less than 0.01 N, or less than 0.001 N after in vivo insertion because Applicant has not disclosed the claimed buckling force ranges provide an advantage, are used for a particular purpose, or solve a stated problem. As no evidence has been provided to the contrary, one of ordinary skill in the art would have expected Applicant's invention to perform equally well with the buckling forces otherwise yielded by the Young's modulus values of Wolfe as modified above because either arrangement enables the sensor to be mechanically compliant with the target tissue when inserted/implanted (Kaplan, ¶ [0067]). Alternatively/Additionally, buckling force is a function of at least Young's modulus, which provides a quality that can be optimized (e.g., compliance with target tissue in vivo). Since the Young's modulus values, and therefore the buckling forces yielded thereby, provide such a quality, the specific claimed ranges of buckling forces after in vivo insertion of the sensor would have been obvious because it has been held that the discovery of optimum or workable ranges by routine experimentation is not inventive. See MPEP 2144.05(II). Regarding claim 10, Wolfe as modified discloses/suggests the conductive material is selected from the group consisting of carbon, conductive polymer, platinum, platinum-iridium, gold, palladium, iridium, and combinations thereof (¶¶ [0011]-[0012] a first sensor wire is selected from the group consisting of platinum, iridium, iridium oxide, and palladium). Regarding claim 11, Wolfe as modified discloses/suggests the analyte sensor further comprises a layer of insulating material covering at least a portion of the layer of conductive material, wherein the working electrode is formed in part by a window in the layer of insulating material that exposes an electrode portion of the layer of conductive material (¶¶ [0094]-[0097] electrode areas, or electrodes, are formed on the wires by removing a portion of the electrically insulating layer that has been extruded over the wire, wherein typically one of these electrodes is a working electrode). Claim(s) 1 and 11-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over US 2013/0245412 A1 (previously cited, Rong) in view of Wolfe and Simpson. Regarding claims 1 and 11-12, Rong discloses and/or suggests an analyte sensor system comprising: an analyte sensor configured for in vivo use (e.g., Fig. 1), the analyte sensor comprising: an elongated core (core 110) comprising a layer of conductive material covering at least a portion of the elongated core (first layer 112 formed of a conductive material); a layer of insulating material covering at least a portion of the layer of conductive material (second layer 104 formed of an insulating material), wherein a working electrode is formed on the elongated core in part by a window in the layer of insulating material that exposes an electrode portion of the layer of conductive material (¶ [0152] working electrode is exposed via window 106, e.g., Fig. 1C); an additional conductive layer covering at least a portion of the layer of insulating material (third layer 114 comprising a conductive material), the additional conductive layer comprising a reference electrode (¶ [0153] third layer may comprise a reference electrode); and a membrane covering at least a portion of the working electrode, wherein the membrane comprises an enzyme layer (membrane 108 covering at least the working electrode; ¶ [0130]); and an inserter needle having a lumen in which the analyte sensor is disposed, and a sharpened distal tip configured to pierce skin of a host, wherein the analyte sensor is configured to be at least partially inserted into the skin of the host from the lumen of the inserter needle, and wherein the inserter needle is withdrawn from the skin of the host after the in vivo insertion of the analyte sensor (e.g., ¶ [0189] needle to implant the sensor and then slide over the sensor when the needle is withdrawn). Rong does not expressly disclose the system further comprises a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor. Wolfe discloses a system comprising an analyte sensor; an inserter needle having a lumen in which the analyte sensor is disposed, and a sharpened distal tip configured to pierce skin of a host (¶¶ [0089] needle carrying/enclosing the sensor; Fig. 5, needle 514; ¶ [0208] needle used to insert sensor; etc.), wherein the analyte sensor is configured to be at least partially inserted into the skin of the host from the lumen of the inserter needle, and wherein the inserter needle is withdrawn from the skin of the host after the in vivo insertion of the analyte sensor (¶ [0129]; ¶ [0208]; etc.); and a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor (insertion tool 560; ¶ [0129]; ¶ [0208]; etc.). It would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Rong with the inserter needle and sensor deployment mechanism disclosed/suggested by Wolfe in order to facilitate inserting the sensor into a target tissue (Rong, ¶ [0189]; Wolfe, ¶ [0090]; etc.). Rong as modified does not expressly disclose the analyte sensor is configured to transform from a freestanding sensor to a non-freestanding sensor responsive to in vivo hydration of the analyte sensor. However, Rong does disclose the core may comprise a polymer (e.g., ¶ [0150]). Wolfe discloses an analyte sensor comprising a core of a shape memory material enables a sensor to be stiffer during implant and then soften during wear (e.g., ¶ [0089]). Simpson discloses and/or suggests a polymer configured to transform from a freestanding configuration to a non-freestanding configuration in response to in vivo hydration (e.g., ¶ [0428] material that is in a rigid state when dehydrated and/or at room temperature and becomes soft and flexible when exposed to body temperature and/or hydration, e.g., hydrophilic polymers, shape memory polymers, etc.). It would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Rong with the analyte sensor being configured to transform from a freestanding sensor to a non-freestanding sensor responsive to in vivo hydration of the analyte sensor as disclosed and/or suggested by Simpson (e.g., carrier substrate 112 comprising a hydrophilic polymer, shape memory polymer, etc.) in order to enable the analyte sensor to be stiffer during insertion and soften during wear (Wolfe, ¶ [0089]). Claim(s) 1 and 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over US 2013/0056144 A1 (Kotzan) in view of Wolfe and Simpson. Regarding claims 1 and 13, Kotzan discloses and/or suggests an analyte sensor system comprising: an analyte sensor configured for in vivo use (Abstract, implantable) and formed from a plurality of substantially planar layers (Fig. 2), said analyte sensor comprising: an elongated core (carrier substrate 112); a layer of conductive material covering at least a portion of the elongated core (contact layer 116); a working electrode disposed on the elongated core (electrode 136); and a membrane covering at least a portion of the working electrode, wherein the membrane comprises an enzyme layer (electrode system 132 having an enzyme, such as glucose oxidase, ¶ [0072]); and an inserter needle having a sharpened distal tip configured to pierce skin of a host, wherein the analyte sensor is configured to be at least partially inserted into the skin of the host using the inserter needle (¶ [0087] insertion needle). Kotzan does not expressly disclose the inserter needle has a lumen in which the analyte sensor is disposed, wherein the analyte sensor is configured to be at least partially inserted into the skin of the host from the lumen of the inserter needle, and wherein the inserter needle is withdrawn from the skin of the host after the in vivo insertion of the analyte sensor; or the system further comprises a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor. Wolfe discloses a system comprising an analyte sensor; an inserter needle having a lumen in which the analyte sensor is disposed, and a sharpened distal tip configured to pierce skin of a host (¶¶ [0089] needle carrying/enclosing the sensor; Fig. 5, needle 514; ¶ [0208] needle used to insert sensor; etc.), wherein the analyte sensor is configured to be at least partially inserted into the skin of the host from the lumen of the inserter needle, and wherein the inserter needle is withdrawn from the skin of the host after the in vivo insertion of the analyte sensor (¶ [0129]; ¶ [0208]; etc.); and a sensor deployment mechanism configured to insert the inserter needle and the analyte sensor into the skin of the host from the lumen of the inserter needle and withdraw the inserter needle from the skin of the host after the in vivo insertion of the analyte sensor (insertion tool 560; ¶ [0129]; ¶ [0208]; etc.). It would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Kotzan with the inserter needle and sensor deployment mechanism disclosed/suggested by Wolfe in order to facilitate inserting the sensor into a target tissue (Kotzan, ¶ [0087]; Wolfe, ¶ [0090]; etc.). Kotzan as modified does not expressly disclose the analyte sensor is configured to transform from a freestanding sensor to a non-freestanding sensor responsive to in vivo hydration of the analyte sensor. However, Kotzan does disclose the core may comprise a polymer (e.g., ¶ [0069]). Wolfe discloses an analyte sensor comprising a core of a shape memory material enables a sensor to be stiffer during implant and then soften during wear (e.g., ¶ [0089]). Simpson discloses and/or suggests a polymer configured to transform from a freestanding configuration to a non-freestanding configuration in response to in vivo hydration (e.g., ¶ [0428] material that is in a rigid state when dehydrated and/or at room temperature and becomes soft and flexible when exposed to body temperature and/or hydration, e.g., hydrophilic polymers, shape memory polymers, etc.). It would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Kotzan with the analyte sensor being configured to transform from a freestanding sensor to a non-freestanding sensor responsive to in vivo hydration of the analyte sensor as disclosed and/or suggested by Simpson (e.g., carrier substrate 112 comprising a hydrophilic polymer, shape memory polymer, etc.) in order to enable the analyte sensor to be stiffer during insertion and soften during wear (Wolfe, ¶ [0089]). Claim(s) 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wolfe (or Wolfe in view of Kaplan) as applied to claim(s) 1 above, and further in view of WO 2017/004531 A1 (previously cited, Rogers). Regarding claim 8, Wolfe as modified teaches/suggests the limitations of claim 1, as discussed above, but does not expressly disclose the elongated core has a flexural modulus of between 0.1 and 300 kPa after the in vivo insertion. However, as discussed above, Wolfe as modified discloses the sensor may be designed to focus on softness and flexibility (Wolfe, ¶ [0089]), compliance with surrounding tissue (Kaplan, ¶ [0067]), etc. Rogers discloses an implantable device may be considered "soft" when bulk properties such as Young's modulus and bending modulus are tailored to minimize the transmission of undue physical stresses and forces on surrounding tissue (¶ [0006]), disclosing the bulk properties may be matched to soft tissue, such as between 0.1 and 300 kPa (e.g., ¶ [0022], ¶ [0024], etc.). Accordingly, similar to the disclosure of Kaplan with respect to Young's modulus, Rogers discloses the bending (flexural) modulus of an in vivo device while in the body similarly provides a quality which can be optimized (i.e., reducing stress and/or force on surrounding tissue). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the analyte sensor of Wolfe with the elongated core having a flexural modulus between 0.1 kPa and 300 kPa after in vivo insertion as disclosed/suggested by Rogers in order to reduce/further reduce stress/force on surrounding tissue (Rogers, ¶ [0006]) and/or because it has been held that the discovery of optimum or workable ranges by routine experimentation is not inventive. See MPEP 2144.05(11). Claim(s) 14-15 and 19-25 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wolfe (or Wolfe in view of Kaplan) as applied to claim(s) 1 above, and further in view of US 2014/0213866 A1 (previously cited, Simpson). Regarding claims 14-15, Wolfe as modified discloses/suggests the limitations of claim 1, as discussed above, but neither expressly discloses the analyte sensor is configured to transform in response to in vivo hydration and further configured to transform from a freestanding sensor to a non-freestanding sensor responsive to a temperature change across a transition temperature, wherein the transition temperature is between 78° and 98° F, nor expressly discloses the elongated core comprises an elongated polymer core or an elongated fiber core. Simpson discloses/suggests a polymer configured to transform from a freestanding configuration to a non-freestanding configuration in response to in vivo hydration and a temperature change across a transition temperature (e.g., ¶ [0428] material that is in a rigid state when dehydrated and/or at room temperature and becomes soft and flexible when exposed to body temperature and/or hydration, e.g., hydrophilic polymers, shape memory polymers, etc.). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the analyte sensor of Wolfe with the elongated core comprising a polymer (e.g., hydrophilic polymer(s), shape memory polymer(s), etc.), such that the analyte sensor is configured to transform in response to in vivo hydration and a temperature change across a transition temperature (e.g., body temperature) as disclosed/suggested by Simpson as a simple substitution of one suitable transformable material for another to yield no more than predictable results. See MPEP 2143(I)(B). Wolfe as modified does not expressly disclose the transition temperature is between 78° and 98° F. Rather, as noted above, Simpson (or Wolfe as modified thereby) discloses the transition temperature is "body temperature" (e.g., ¶ [0428]), which Simpson discloses is 37° C, or 98.6° F (e.g., ¶ [0398]). However, it has been held that a prima facie case of obviousness exists where the claimed ranges or amounts do not overlap with the prior art but are merely close. See MPEP 2144.05(I). Accordingly, since the disclosed transition temperature is less than a degree from the claimed range, at least the upper end of said range would have been obvious because the transition temperatures are so close that one of ordinary skill in the art would expect the analyte sensor disclosed by Simpson (or Wolfe as modified thereby) and the claimed analyte sensor to provide the same result (e.g., transforming to the analyte sensor to a flexible, non-freestanding state after insertion in vivo). Alternatively/Additionally, at the time the invention was effectively filed, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the analyte sensor of Wolfe with the transition temperature being between 78-98° F because Applicant has not disclosed the claimed temperature range provides an advantage, is used for a particular purpose, or solves a stated problem. Rather, Applicant discloses a larger transition temperature range of 78-100° F is suitable (e.g., ¶ [0165]). As no evidence has been provided to the contrary, one of ordinary skill in the art would have expected Applicant's invention to perform equally well with the transition temperature disclosed by Simpson (or Wolfe as modified thereby) because either arrangement ensures the analyte sensor does not buckle or deform during chemistry/enzyme application (Wolfe, ¶ [0089], ¶ [0066]; etc.), during sensor insertion through tissue (Kaplan, ¶ [0065]) to precisely reach a target region of tissue (Kaplan, ¶ [0065]), etc., while enabling the sensor to be mechanically compliant with the target tissue when inserted/implanted (Kaplan, ¶ [0067]). Regarding claims 19-20, Wolfe as modified discloses/suggests but does not expressly disclose the elongated polymer core has a Young's modulus less than 5 GPa or less than 2 GPa before the in vivo insertion. However, at the time the invention was effectively filed, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Wolfe with the elongated polymer core having a Young's modulus less than 2 GPa before the in vivo insertion because Applicant has not disclosed that the claimed range provides an advantage, is used for a particular purpose, or solves a stated problem. As no evidence has been provided to the contrary, one of ordinary skill in the art would have expected Applicant's invention to perform equally well with the elongated polymer core having any Young's modulus before the in vivo insertion that enables the sensor to be sufficiently "freestanding" (e.g., holding its shape during manufacturing processes, holding its shape during insertion through tissue, etc.) because either arrangement permits to be relatively stiff ex vivo and relatively flexible in vivo. Alternatively/Additionally, Kaplan discloses, before in vivo insertion, the component may have a Young's modulus at least comparable or up to 90% greater than that of a target tissue (e.g., ¶ [0064]). Since Applicant acknowledges the elastic modulus of subcutaneous tissue is known or reported to be 0.12-23 kPa (e.g., ¶ [0122]), it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the sensor system of Wolfe with the elongated polymer core having a Young's modulus less than 2 GPa before the in vivo insertion (e.g., 0.12 kPa – 47.7 kPa) as disclosed/suggested by Kaplan in order to provide the sensor with sufficient stiffness for penetrating subcutaneous tissue during insertion therein (Kaplan, ¶ [0122]). Regarding claim 21, Wolfe as modified discloses/suggests the layer of conductive material is a conductive trace that runs along a length of the elongated polymer core or the elongated fiber core (¶ [0089] wires 401 coil around a central core 402, e.g., Fig. 10), wherein a portion of the conductive trace comprises the working electrode (¶¶ [0094]-[0097] electrode areas, or electrodes, are formed on the wires by removing a portion of the electrically insulating layer that has been extruded over the wire, wherein typically one of these electrodes is a working electrode). Regarding claim 22, Wolfe as modified discloses/suggests the elongated polymer core comprises an elongated elliptical polymer core (Wolfe, ¶ [0009] core is cylindrical, which one of ordinary skill in the art would readily appreciate encompasses circular and elliptical cross sections) and wherein at least one conductive trace runs along the elongated elliptical polymer core (e.g., ¶ [0089] wires 401 coil around a central core 402). Regarding claims 23-25, Wolfe as modified teaches/suggests the limitations of claim 15, as discussed above. Since none of claims 15 and 23-25 require the analyte sensor to comprise an elongated fiber core, Wolfe as modified further meets the limitations of claims 23-25. Response to Arguments Applicant's arguments have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion The prior art made of record and not relied upon is considered pertinent to Applicant's disclosure: see attached PTO-892. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Meredith Weare whose telephone number is 571-270-3957. The examiner can normally be reached Monday - Friday, 9 AM - 5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. Applicant is encouraged to use the USPTO Automated Interview Request at http://www.uspto.gov/interviewpractice to schedule an interview. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tse Chen, can be reached on 571-272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Meredith Weare/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 13 earlier events
Jul 01, 2025
Applicant Interview (Telephonic)
Jul 03, 2025
Response Filed
Oct 20, 2025
Final Rejection mailed — §103, §112
Jan 20, 2026
Request for Continued Examination
Feb 10, 2026
Response after Non-Final Action
Feb 24, 2026
Non-Final Rejection mailed — §103, §112
May 22, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797003
Strategic Treatment of Pressure Ulcer Using Sub-Epidermal Moisture Values
3y 0m to grant Granted Nov 17, 2026
Patent 12765837
RESPIRATORY DISEASE MONITORING WEARABLE APPARATUS
4y 8m to grant Granted Oct 20, 2026
Patent 12765773
DEVICE FOR ACQUIRING PHYSIOLOGICAL VARIABLES MEASURED IN A BODY
2y 2m to grant Granted Oct 20, 2026
Patent 12758154
SENSOR STABILIZER
3y 8m to grant Granted Oct 13, 2026
Patent 12745931
OCCLUSION DEVICE WITH SENSING FUNCTIONALITY
5y 1m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
51%
Grant Probability
82%
With Interview (+31.7%)
3y 10m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 726 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month